Showing 1 posts of 1 posts found.


Sosei Heptares announces first subject dosed in phase 1 trial for schizophrenia therapy

July 3, 2023
Research and Development HTL'149, Neurology, Sosei Heptares, clinical trial, schizophrenia

Sosei Heptares has announced that it has dosed its first patient in its phase 1 trial evaluating HTL0048149 (HTL’149), a …

Latest content